Cabbacis, a US federal licensed tobacco product manufacturer that focuses on reducing the harmful effects of its products, has announced that Canada's Intellectual Property Office (CIPO) has granted a patent for its pod. The pod contains a mixture of very low nicotine tobacco and cannabis for use in electronic cigarettes.
The Canadian Patent number 3,151,047 has been granted to Cabbacis, which includes 27 claims and will expire on September 10, 2040. In early 2022, the Canadian Intellectual Property Office (CIPO) also granted Patent number 3,107,796 to Cabbacis for cigarettes containing a mixture of extremely low nicotine tobacco and cannabis.
We are thrilled that both of our products have now received patents in Canada, which was one of our early target countries for commercialization," said Joseph Pandolfino, founder and CEO of Cabbacis.
The company's ultra-low nicotine cigarettes and soon-to-be-released electronic pods containing a mix of ultra-low nicotine tobacco and cannabis are primarily aimed at helping traditional cigarette smokers reduce their smoking habit and transition to less harmful tobacco nicotine products or quit nicotine altogether.
Cabbacis has a portfolio of patents that includes 25 authorized patents and various pending patent applications in the United States, Europe, China, Japan, South Korea, Canada, Australia, New Zealand, Mexico, Brazil, and other countries and regions. The company already owns six patents in the United States.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
